Monday, 02 Nov 2020 04:36 PM MYT
MOSCOW, Nov 2 — Russian drugmaker Pharmasyntez has asked the Kremlin for permission to produce a generic version of US firm Gilead Sciences’s Covid-19 treatment remdesivir without а patent, the Vedomosti newspaper reported on Monday. But it was not able to produce the drug as it is protected by a patent and Gilead did not respond to a request for a voluntary licence, Vedomosti reported, citing a letter sent by Punia to several Russian ministries.The Russian firm has completed a clinical trial of the generic drug, labelled Remdeform, on 300 patients across 23 Russian hospitals, a register entry showed.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: